Based on DrugBank information (https://go.drugbank.com/), 5 drugs (adapalene, entrectinib, irinotecan, lurasidone, and nilotinib) cross BBB and during PD could find use as inhibitors of the “TNF-α signaling via NF-κB” pathway. Here, NFKB1 is linked to Parkinson disease.